The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1533
The full issue is available to subscribers Subscriber Login   
Guselkumab (Tremfya) for Psoriasis

The FDA has approved the interleukin (IL)-23 blocker guselkumab (Tremfya – Janssen) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Guselkumab is the first selective IL-23 blocker to become available in the US.

MECHANISM OF ACTION — IL-23 is a cytokine involved in normal inflammatory and immune responses. Guselkumab is a fully human monoclonal IgG1 antibody that selectively binds to the p19 subunit of IL-23, inhibiting it from binding to the IL-23 receptor and preventing downstream release of pro-inflammatory cytokines (such as IL-17A) and chemokines.

STANDARD TREATMENT — Plaque psoriasis is a chronic, inflammatory, immune-mediated disorder. Mild to moderate psoriasis is generally treated with topical corticosteroids. Topical vitamin D analogs and the retinoid tazarotene (Tazorac, and others) ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this issue:
Title: Issue 1533
Select version:
 Downloadable, electronic issue - $35
 Postal, hardcopy issue - $35